Tecan Enhances Specialty Diagnostics Portfolio With ELISA Kit Asset Acquisition Tecan Group (SIX Swiss Exchange: TECN) has announced a strategic agreement to acquire key ELISA immunoassay assets from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics…
Columbus Unites to Support Life-Saving Research and Patient Care at the 2025 Susan G. Komen Race for the Cure Susan G. Komen®, the world’s leading breast cancer organization, has announced the return of its signature Race for the Cure event…
Personalized Cancer Vaccine Market & Clinical Trials Outlook 2025 – 18+ Vaccines in Development The “Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025″ report, now available from ResearchAndMarkets.com, highlights the growing significance of personalized cancer vaccines in the…
Neurogene Publishes Study on NGN-401 Gene Therapy for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company dedicated to developing transformative genetic medicines for patients suffering from rare neurological disorders, has announced the publication of a peer-reviewed study detailing…
RenovoRx Announces First RenovoCath Revenues & Phase III Trial Update RenovoRx, Inc. (Nasdaq: RNXT), a leading life sciences company focused on developing innovative targeted oncology therapies, has announced its financial results and key business updates for the fourth quarter and…
Unlearn and Trace Neuroscience Collaborate to Enhance ALS Clinical Trials Unlearn®, a leader in AI-powered solutions for clinical trials, has announced a strategic collaboration with Trace Neuroscience, a biotechnology company specializing in genomic therapies for neurodegenerative diseases. This partnership is…
ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer The first patient has been successfully dosed in the DESTINY-Gastric05 phase 3 trial, which aims to evaluate the efficacy and safety of ENHERTU® (trastuzumab deruxtecan) in combination with…
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker Eli Lilly has made a groundbreaking advancement in cardiovascular medicine with its investigational small interfering RNA (siRNA) therapeutic, lepodisiran, which demonstrated a remarkable ability to reduce lipoprotein(a) [Lp(a)] levels…
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment BeiGene, Ltd., a global oncology company soon to be rebranded as BeOne Medicines Ltd., has announced a significant milestone in its efforts to expand cancer treatment options. The Committee for…
Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal 3475A-D77 Phase 3 trial evaluating subcutaneous pembrolizumab in combination with…
Novotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024) Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its latest preclinical report exploring the rapidly evolving landscape of small interfering RNA…
Blue Lake Biotechnology’s Intranasal COVID-19 Vaccine Candidate Demonstrates Long-Lasting Immunity and Broad Protection Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company specializing in intranasal vaccine development, along with its affiliate CyanVac LLC, recently published two pivotal preclinical studies in the…